A trial looking at the timing of transplants using a patient's own stem cells (autologous transplant) for chronic lymphocytic leukaemia (MRC CLL 5)

Cancer type:

Blood cancers
Chronic leukaemia
Chronic lymphocytic leukaemia (CLL)




Phase 3

This trial looked to find the best stage in your treatment plan to have a stem cell or bone marrow transplant for people with chronic lymphocytic leukaemia (CLL).

Doctors usually treat CLL with chemotherapy. This may bring your leukaemia under control, which is called ‘remission’. But the leukaemia is likely to come back and need further treatment.

Some people with CLL have ‘high risk’ leukaemia. This means that there is a high risk that their leukaemia will come back. So they may need more intensive treatment at some point. This involves having chemotherapy to put your CLL into remission again. And then high dose chemotherapy and a stem cell or bone marrow transplant. This treatment is usually only suitable for younger, fitter patients.

For high risk patients, doctors do not know whether it is better to use intensive treatment earlier rather than waiting until the leukaemia comes back. The aim of this trial was to find out if having a stem transplant earlier for high risk patients means that the leukaemia is less likely to come back long term.

Summary of results

The trial team found that the patients in this trial who had high dose chemotherapy and a stem cell transplant did no better overall than the patients who did not.

223 people with high risk CLL took part in the trial. Everybody had early chemotherapy and then

  • Half had high dose chemotherapy and a stem cell transplant with their own cells (autologous transplant)
  • Half had no further treatment but had regular checkups with their doctors to keep a close eye on their leukaemia

The researchers analysed the early results in 2009. They compared the results of the 2 different groups. They found that having a stem cell transplant halved the risk of the leukaemia coming back or getting worse in people with high risk CLL. But overall there was no difference in the number of people who lived for more than 5 years after treatment.

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) but may not have been published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Donald Milligan

Supported by

European Blood and Bone Marrow Transplant Group
Experimental Cancer Medicine Centre (ECMC)
Medical Research Council (MRC)
National Institute for Health Research Cancer Research Network (NCRN)

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 322

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think